NUPLAZID® (pimavanserin) logo - once daily - 34 mg capsules
NUPLAZID® (pimavanserin) logo - once daily - 34 mg capsules NUPLAZID® (pimavanserin) logo - once daily - 34 mg capsules

2

Table shows select study details of the Mosholder study
Table shows select study details of the Mosholder study

Graph shows all-cause mortality risk for up to 360 days of follow-up for NUPLAZID® vs off-label atypical antipsychotics
Graph shows all-cause mortality risk for up to 360 days of follow-up for NUPLAZID® vs off-label atypical antipsychotics

Chart shows hazard ratio of all-cause mortality risk overall and by time interval for NUPLAZID® vs off-label atypical antipsychotics
Chart shows hazard ratio of all-cause mortality risk overall and by time interval for NUPLAZID® vs off-label atypical antipsychotics

Table shows select sensitivity analyses findings from the publication
Table shows select sensitivity analyses findings from the publication

3

Table shows select study details of the Layton study
Table shows select study details of the Layton study

Chart shows overall cumulative all-cause mortality risk in patients treated with NUPLAZID® vs off-label atypical antipsychotics
Chart shows overall cumulative all-cause mortality risk in patients treated with NUPLAZID® vs off-label atypical antipsychotics

Chart shows hazard ratio of all-cause mortality risk for primary cohort and subcohort, overall and by follow-up period, for NUPLAZID® vs off-label atypical antipsychotics
Chart shows hazard ratio of all-cause mortality risk for primary cohort and subcohort, overall and by follow-up period, for NUPLAZID® vs off-label atypical antipsychotics